vs
Side-by-side financial comparison of Citius Pharmaceuticals, Inc. (CTXR) and Moolec Science SA (MLEC). Click either name above to swap in a different company.
Citius Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($3.9M vs $2.6M, roughly 1.5× Moolec Science SA). Moolec Science SA runs the higher net margin — -91.8% vs -238.2%, a 146.3% gap on every dollar of revenue.
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative prescription therapies addressing unmet medical needs across critical care, oncology, anti-infective treatment, and supportive care segments, primarily serving the U.S. healthcare market.
Moolec Science SA is a global agricultural biotechnology and food technology company specializing in molecular farming. It uses engineered crop platforms to produce sustainable, cost-competitive animal-derived proteins for use in alternative meat, dairy products and food ingredients, serving food manufacturers, agribusinesses and consumer goods brands across North America, Europe and Latin America.
CTXR vs MLEC — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.9M | $2.6M |
| Net Profit | $-9.4M | $-2.4M |
| Gross Margin | 80.0% | -25.5% |
| Operating Margin | -228.7% | -77.9% |
| Net Margin | -238.2% | -91.8% |
| Revenue YoY | — | — |
| Net Profit YoY | 8.6% | — |
| EPS (diluted) | $-0.38 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $3.9M | — | ||
| Q4 24 | — | $2.6M | ||
| Q3 23 | — | $1.7M |
| Q4 25 | $-9.4M | — | ||
| Q4 24 | — | $-2.4M | ||
| Q3 23 | — | $-1.6M |
| Q4 25 | 80.0% | — | ||
| Q4 24 | — | -25.5% | ||
| Q3 23 | — | 12.7% |
| Q4 25 | -228.7% | — | ||
| Q4 24 | — | -77.9% | ||
| Q3 23 | — | -130.3% |
| Q4 25 | -238.2% | — | ||
| Q4 24 | — | -91.8% | ||
| Q3 23 | — | -91.4% |
| Q4 25 | $-0.38 | — | ||
| Q4 24 | — | $-0.06 | ||
| Q3 23 | — | $-0.04 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.7M | $1.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $80.0M | $2.8M |
| Total Assets | $140.4M | $31.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.7M | — | ||
| Q4 24 | — | $1.9M | ||
| Q3 23 | — | $853.6K |
| Q4 25 | $80.0M | — | ||
| Q4 24 | — | $2.8M | ||
| Q3 23 | — | $8.9M |
| Q4 25 | $140.4M | — | ||
| Q4 24 | — | $31.4M | ||
| Q3 23 | — | $22.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-13.0M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-13.0M | — | ||
| Q4 24 | — | — | ||
| Q3 23 | — | $-1.7M |
| Q4 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 23 | — | $-1.8M |
| Q4 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 23 | — | -106.2% |
| Q4 25 | — | — | ||
| Q4 24 | — | 4.4% | ||
| Q3 23 | — | 6.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
